BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30861607)

  • 1. MDM2 and its functional polymorphism SNP309 contribute to the development of esophageal carcinoma.
    Xiao FK; Guo S; Yang F; Zhao LS; Wang LD
    J Gene Med; 2019 May; 21(5):e3086. PubMed ID: 30861607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between SNP309 and del1518 Polymorphism in MDM2 Homologue and Esophageal Squamous Cell Carcinoma Risk in Chinese Population of Shandong Province.
    Zhang L; Zhu Z; Wu H; Wang K
    Ann Clin Lab Sci; 2015; 45(4):433-7. PubMed ID: 26275695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan.
    Yueh TC; Hung YW; Shih TC; Wu CN; Wang SC; Lai YL; Hsu SW; Wu MH; Fu CK; Wang YC; Ke TW; Chang WS; Tsai CW; Bau DT
    Cancer Genomics Proteomics; 2018; 15(5):405-411. PubMed ID: 30194081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC).
    Yang J; Liu B; Li W; Xiong H; Qiu H; Fu Q; Chen B; Hu G; Yuan X
    Cancer Epidemiol; 2013 Oct; 37(5):629-33. PubMed ID: 23837945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
    Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
    Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.
    Hong Y; Miao X; Zhang X; Ding F; Luo A; Guo Y; Tan W; Liu Z; Lin D
    Cancer Res; 2005 Oct; 65(20):9582-7. PubMed ID: 16230424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
    Wan Y; Wu W; Yin Z; Guan P; Zhou B
    BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
    Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
    Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
    Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
    BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
    Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
    DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
    Wang ML; Xu YX; Qian J; Wang FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.
    Varmazyar S; Marashi SM; Shoja Z; Tornesello ML; Buonaguro FM; Shahmahmoodi S; Safaie-Naraghi Z; Jalilvand S
    Med Microbiol Immunol; 2017 Apr; 206(2):157-163. PubMed ID: 28083704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis.
    Ma Y; Bian J; Cao H
    PLoS One; 2013; 8(2):e56918. PubMed ID: 23451111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS; Miller CW; Karlan BY; Koeffler HP
    Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.